To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

Clinical trial NCT06756269 · RECRUITING

Trial details

NCT number: NCT06756269
Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HPV Infection HPV-Related Carcinoma HPV-Related Intraepithelial Neoplasia Genital Wart

Start date: 2025-01-15
Primary completion: 2025-10-30
Enrollment: 330

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.